Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Dwarfism, Pituitary 1Diabetes Mellitus, Type 2 1

Interventions

Surveys and Questionnaires 53Blood Specimen Collection 53Specimen Handling 28Radiotherapy 18Observation 18Interviews as Topic 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Drug Therapy 10Data Collection 10Biopsy 10Tomography, X-Ray Computed 9darolutamide 8Watchful Waiting 7Standard of Care 7ribociclib 6palbociclib 6Restraint, Physical 6Patient Reported Outcome Measures 6Magnetic Resonance Imaging 6Immune Checkpoint Inhibitors 6trastuzumab deruxtecan 5Positron-Emission Tomography 5Mass Screening 5Genetic Testing 5Esophagectomy 5Breath Tests 5Bevacizumab 5enzalutamide 4apalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × somapacitan × 90 days × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡